Company facts
- Industry
- Pharmaceutical Preparations
- Headquarters
- Zug
- Most recent report
- 8-K, filed Sep 30, 2026
- Filings on record
- 329 filings
- On EDGAR
- CIK 1821586
- Fiscal year ends
- December
- Filer status
- Large accelerated filer
Financials 8 of 27
News 8 of 54
Prospectuses and Registrations 8 of 28
- S-8 Registration statement for an employee plan Aug 10, 2026
- S-3ASR Automatic shelf registration Aug 10, 2026
- 424B5 Prospectus supplement for an offering Jun 24, 2026
- 424B5 Prospectus supplement for an offering Jun 22, 2026
- 424B5 Prospectus supplement for an offering Nov 5, 2025
- S-3 Shelf registration statement Aug 31, 2023
- 424B5 Prospectus supplement for an offering Jun 29, 2023
- 424B3 Prospectus supplement for an offering Jun 27, 2023
Proxies 8 of 17
- DEFA14A Extra proxy material Apr 21, 2026
- DEF 14A Proxy statement for a shareholder vote Apr 21, 2026
- DEFA14A Extra proxy material Apr 22, 2025
- DEF 14A Proxy statement for a shareholder vote Apr 22, 2025
- DEFA14A Extra proxy material Apr 24, 2024
- DEF 14A Proxy statement for a shareholder vote Apr 24, 2024
- DEFA14A Extra proxy material Apr 26, 2023
- DEF 14A Proxy statement for a shareholder vote Apr 26, 2023
Ownership 8 of 156
- SCHEDULE 13G/A Large holder reported a passive stake, amended Aug 14, 2026
- SCHEDULE 13G Large holder reported a passive stake Aug 14, 2026
- SCHEDULE 13G/A Large holder reported a passive stake, amended Aug 14, 2026
- 4 Insider reported a trade Jul 29, 2026
- 4 Insider reported a trade Jul 23, 2026
- 4 Insider reported a trade Jul 21, 2026
- 4 Insider reported a trade Jul 20, 2026
- 144 Notice of a proposed sale of restricted stock Jul 15, 2026
Other 8 of 47
- ARS Annual report sent to shareholders Apr 21, 2026
- ARS Annual report sent to shareholders Apr 22, 2025
- UPLOAD Comment letter from SEC staff May 13, 2024
- CORRESP Reply to SEC staff May 7, 2024
- UPLOAD Comment letter from SEC staff Apr 29, 2024
- ARS Annual report sent to shareholders Apr 24, 2024
- EFFECT Notice that a registration became effective Sep 11, 2023
- CORRESP Reply to SEC staff Sep 7, 2023
Everything here comes from MoonLake Immunotherapeutics's own filings on SEC EDGAR. The filing list is rechecked every hour.